Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
Pfizer's Paxlovid will not be included in China's national insurance
10:34pm, Monday, 09'th Jan 2023
TAIPEI, Taiwan — Chinese health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price t
Moderna's Interim Earnings Beat Modestly, Uncertainty Looms Over 2023
07:57pm, Monday, 09'th Jan 2023 Benzinga
Moderna Inc (NASDAQ: MRNA) reported interim FY22 COVID-19 vaccine sales of $18.4 billion against $18-19 billion forecasted in the Q3 earnings release and the consensus of $17.8 billion.
The company
4 Top Small-Cap U.S. Index Funds to Buy in 2023
07:48pm, Monday, 09'th Jan 2023 The Motley Fool
Make small-cap investing easy.
Moderna, CureVac and Ocugen offer updates on COVID vaccines, while China cracks down on critics of government's pandemic response
07:19pm, Monday, 09'th Jan 2023 MarketWatch
A flurry of vaccine announcements dominated pandemic headlines on Monday
FDA Accepts Pfizer's (PFE) sBLA Filing for Pneumococcal Jab
03:37pm, Monday, 09'th Jan 2023 Zacks Investment Research
The FDA grants priority review to Pfizer's (PFE) filing seeking label expansion of its pneumococcal 20-valent conjugate vaccine in infants and children. A decision is expected by this April.
General Motors And These 2 Healthcare Majors On CNBC's 'Final Trades'
01:17pm, Monday, 09'th Jan 2023 Benzinga
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management named Pfizer Inc. (NYSE: PFE), saying that it offers "growth at a reasonable price."
Benzinga's analyst
FDA Accepts Pfizer's (PFE) sBLA Filing for Pneumococcal Jab
12:03pm, Monday, 09'th Jan 2023
The FDA grants priority review to Pfizer's (PFE) filing seeking label expansion of its pneumococcal 20-valent conjugate vaccine in infants and children. A decision is expected by this April.
Pfizer CEO: 2022 was one of the most successful years in our corporate history
11:28am, Monday, 09'th Jan 2023
CNBC's Meg Tirrell sits down with Pfizer CEO Albert Bourla to discuss the Covid crisis and Pfizer's future in producing 19 new products in the next 18 months.
This Stock Could Be a Surprise Growth Pick for 2023
10:30am, Monday, 09'th Jan 2023 The Motley Fool
Pfizer is about to enter a whole new era of growth.
This Stock Could Be a Surprise Growth Pick for 2023
05:30am, Monday, 09'th Jan 2023
Pfizer is about to enter a whole new era of growth.
The 7 Most Undervalued Value Stocks to Buy Now
12:33pm, Sunday, 08'th Jan 2023
Investors are entering a new era that could very well be dominated by value investing for quite some time. As a result, investors should look for undervalued value stocks to buy now.
My Top Value Stock to Buy In 2023
02:15pm, Saturday, 07'th Jan 2023 The Motley Fool
This company isn't just a "pandemic stock."
I'm Buying the Stocks of These Companies Because of Their Positive Cash Flows
11:35am, Saturday, 07'th Jan 2023
Today, I will be looking at two great companies with significant cash flows to invest in.
My Top Value Stock to Buy In 2023
09:15am, Saturday, 07'th Jan 2023
This company isn't just a "pandemic stock."
Dividend Income Summary: Lanny's December 2022 Summary
04:52am, Saturday, 07'th Jan 2023
A decade of investing is snowballing on its own, but we keep investing as much as we can. In December, we (my wife and I) received a dividend income total of $8,110.03.
